A Case Study Using the BRAT Framework for Benefit Risk Assessment

(1) A Generalization of the NNT/NNH concept

Christoph Dierig
Global Integrated Analysis, Bayer Pharma

(2) Application and visualization of Multi-Criteria Decision Analysis (MCDA).

Richard Nixon
Modeling and Simulation, Novartis

Basler Biometric Section, 25 September 2012
"The processes described and conclusions drawn from the work presented herein relate solely to the \textit{testing} of methodologies and representations for the evaluation of benefit and risk of medicines.

This report neither replaces nor is intended to replace or comment on any regulatory decisions made by national regulatory agencies, nor the European Medicines Agency."
Acknowledgments

- The research leading to these results was conducted as part of the PROTECT consortium (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium, www.imi-protect.eu) which is a public-private partnership coordinated by the European Medicines Agency.

- The PROTECT project has received support from the Innovative Medicine Initiative Joint Undertaking (www.imi.europa.eu) under Grant Agreement n° 115004, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.
A Case Study Using the BRAT Framework for Benefit Risk Assessment

(1) A Generalization of the NNT/NNH concept

Christoph Dierig
Global Integrated Analysis, Bayer Pharma

(2) Application and visualization of Multi-Criteria Decision Analysis (MCDA).

Richard Nixon
Modeling and Simulation, Novartis

Basler Biometric Section, 25 September 2012
Outline

• Introduction
  – IMI PROTECT
  – Tysabri Case Study
  – BRAT FRAMEWORK

• Tysabri Case Study
  – Application of the BRAT Framework

• Quantitative Methods for Benefit-Risk Assessment
  – Generalization of the NNT/NNH concept
IMI (Innovative Medicines Initiative) PROTECT

- PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium)
  - Collaborative European project coordinated by the EMA
  - Multi-national consortium of 32 partners including academics, regulators, and pharmaceutical companies

- Work program 5 (WP5) is focusing on Benefit-Risk integration and representation
  - In wave 1, four case studies were performed (Raptiva, Ketek, Acomplia, Tysabri) to evaluate various frameworks and quantitative methods for benefit-risk assessment
Tysabri Case Study - Background

- Tysabri (natalizumab) was approved in 2004 by the FDA for the treatment of relapsing remitting multiple sclerosis (RRMS).
- In 2005 the drug was suspended because of an associated incidence of progressive multifocal leukoencephalopathy (PML), a rare neurological disorder.
- In 2006 it was re-introduced due to patient demand, but with strict risk minimization measures.
- In 2009, due to occurrence of further PML in monotherapy post marketing, CHMP reassessed the PML risk of Tysabri and confirmed the current approval.
The BRAT Framework for B/R-Assessment

Benefit Risk Action Team (BRAT) framework

- Developed by PhRMA (Pharmaceutical Research & Manufacturers of America)

- Structured **6-step approach** for defining the decision context and selecting, organizing, evaluating, and displaying relevant benefit-risk information

- Process is supported by an EXCEL based tool, however the framework is boarder than the tool
Step 1: Define the Decision Context

Tysabri Case Study

• Decision question:
  • Should Tysabri be given marketing approval at the time of first registration?
  • Should Tysabri be kept on the market given that increased episodes of PML were observed?

• Indication: Relapsing remitting multiple sclerosis

• Drugs to compare: Tysabri vs. (Placebo, Avonex, Copaxone)

• Decision perspective: EMA

• Time frame: 2 years of treatment
Step 2: Identify Benefit and Risk Outcomes – Value Tree Creation

Benefits
- Convenience Benefits
  - Convenience (weight 0.6%)
  - Relapse (weight 3.9%)
- Medical Benefits
  - Disability Progression (weight 5.6%)

Risk Balance
- Infection
  - Reactivation of serious herpes viral
  - PML (weight 55.9%)
- Liver Toxicity
  - Transaminase elevation (weight 11.2%)
- Reproductive Toxicity
  - Congenital abnormalities (weight 5.6%)
- Neurological Disorders
  - Seizures (weight 5.6%)
- Other
  - Infusion/injection reactions
    - Hypersensitivity reactions (weight 1.1%)
    - Flu-like reactions (weight 1.1%)
Step 2: Identify Benefit and Risk Outcomes – Value Tree Creation

- For value tree set-up comprehensive discussion is required
  - Display all benefits and risks relevant for BR assessment
  - Strategy for initial set-up
    - Start with a comprehensive draft value tree
    - Reduce to relevant entries
  - Target Product Profile and Risk Management Plan might be appropriate sources
- Value tree needs to be updated whenever new information on risks or benefits is available
- Creation & modification of value tree are well supported by the BRAT tool
**Step 3: Identify and Extract Source Data**

**Preparing the Data Table**

**Identify**
- Search strategy
- Search query

**Select**
- Study eligibility criteria

**Extract**
- Extraction guidelines

**Aggregate**
- e.g. meta-analysis, placebo-calibration

**Study worksheet**
- one row per study

**Data source table**
- one row per study/treatment/outcome

**Data summary table**
- one row per outcome
For the Tysabri case study three relevant clinical trials were identified:

- Tysabri vs. placebo
- Avonex vs. placebo
- Copaxone vs. placebo

Comparisons of active compounds could be established via “placebo calibration”

*Note: A full network meta-analysis could have been required in a more complex situation*
Step 3: Identify and Extract Source Data

Preparing the Data Table

- By use of filters the BRAT EXCEL tool facilitates consideration of, for example,
  - More than one comparator
  - Several points in time for assessment (here: approval, 2 years post-approval)
  - etc.

<table>
<thead>
<tr>
<th>Comparator</th>
<th>Timepoint</th>
<th>Filter3</th>
<th>Filter4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avonex</td>
<td>At time of approval</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Copaxone</td>
<td>After approval</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Step 3: Identify and Extract Source Data

Preparing the Data Table

<table>
<thead>
<tr>
<th>Outcome name (weight: 3.9%)</th>
<th>Comparator</th>
<th>Timepoint</th>
<th>Filter3</th>
<th>Filter4</th>
<th>Tysabri rate point estimate</th>
<th>Tysabri rate lower CI</th>
<th>Tysabri rate upper CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relapse</td>
<td>Avonex</td>
<td>At time of approval</td>
<td></td>
<td></td>
<td>0.28</td>
<td>0.24</td>
<td>0.31</td>
</tr>
<tr>
<td>Relapse</td>
<td>Copaxone</td>
<td>At time of approval</td>
<td></td>
<td></td>
<td>0.28</td>
<td>0.24</td>
<td>0.31</td>
</tr>
<tr>
<td>Relapse</td>
<td>Placebo</td>
<td>At time of approval</td>
<td></td>
<td></td>
<td>0.28</td>
<td>0.24</td>
<td>0.31</td>
</tr>
</tbody>
</table>

- Data table provides entry fields for:
  - Organizational data (here: outcome, comparator, time point)
  - Data on Tysabri and comparator (active comparator or placebo)
  - Derived measures for risk differences and/or ratios
- Basic error checks are performed by the tool, results are presented in a separate table.
- Non-availability of data is **not** prohibitive for using the tool
Step 4: Customize the Framework

- Update of framework when new information is available
  - Adding/deleting benefits and/or risks
  - Update of quantitative information
- Tuning the value tree
Step 5: Assess Outcome Importance

- Ranking or weighting of individual outcomes according to their importance / severity
  - Forest plot allows different orderings (ranking) of benefit and risk criteria, e.g. according to
    - Point estimate
    - Value tree order

- Weighting is not supported by the BRAT EXCEL tool
  - Information on weights can only be added to the labels
Step 6: Display and Interpret Key Benefit-Risk Metrics

- BRAT tool provides two options for a quantitative overview on benefits and risks focusing on risk differences (or ratios).
  - Key benefit-risk summary table
  - Forest plot

Key Benefit-Risk Summary Table

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Tysabri Risk</th>
<th>Comparator Risk</th>
<th>Risk Difference (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Convenience</td>
<td>0.30</td>
<td>0.26</td>
<td>(0.04, 0.51)</td>
</tr>
<tr>
<td>Mortality</td>
<td>0.10</td>
<td>0.15</td>
<td>(-0.05, 0.35)</td>
</tr>
<tr>
<td>Reason</td>
<td>Responder</td>
<td>0.70</td>
<td>0.60</td>
</tr>
<tr>
<td>Non-Responder</td>
<td>0.30</td>
<td>0.40</td>
<td>(-0.10, 0.05)</td>
</tr>
<tr>
<td>Neurological</td>
<td>Sensory</td>
<td>0.05</td>
<td>0.10</td>
</tr>
<tr>
<td>Motor</td>
<td>Adverse events</td>
<td>0.05</td>
<td>0.03</td>
</tr>
</tbody>
</table>

Forest Plot

Risk Difference (per 1000 patients)
### Key Benefit-Risk Summary Table

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Tysabri Risk / 1000 pts</th>
<th>Comparator Risk / 1000 pts</th>
<th>Risk Difference (95% CI) / 1000 pts</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Benefits</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Convenience Benefits</td>
<td>Convenience (weight 0.6%)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Medical Benefits</td>
<td>Relapse (weight 3.9%)</td>
<td>280</td>
<td>540</td>
</tr>
<tr>
<td></td>
<td>Disability Progression (weight 5.6%)</td>
<td>110</td>
<td>230</td>
</tr>
<tr>
<td><strong>Risks</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infection</td>
<td>Reactivation of serious herpes viral infections (weight 8.7%)</td>
<td>80</td>
<td>70</td>
</tr>
<tr>
<td></td>
<td>PML (weight 55.9%)</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Liver Toxicity</td>
<td>Transaminases elevator (weight 11.2%)</td>
<td>50</td>
<td>40</td>
</tr>
<tr>
<td>Reproductive Toxicity</td>
<td>Congenital abnormalities (weight 5.6%)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Neurological Disorders</td>
<td>Seizures (weight 5.6%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Other</td>
<td>Infusion/Injection reactions (weight 2.8%)</td>
<td>236</td>
<td>180</td>
</tr>
<tr>
<td></td>
<td>Hypersensitivity reactions (weight 1.1%)</td>
<td>90</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>Flu-like reactions (weight 1.1%)</td>
<td>399</td>
<td>400</td>
</tr>
</tbody>
</table>

Higher for Tysabri
Higher for Comparator
Step 6: Display and Interpret Key Benefit-Risk Metrics

Forest Plot

- Convenience (weight 0.6%)
- Relapse (weight 3.9%)
- Disability Progression (weight 5.6%)
- Reactivation of serious herpes viral infections...
- PML (weight 55.9%)
- Transaminases elevation (weight 11.2%)
- Congenital abnormalities (weight 5.6%)
- Seizures (weight 5.6%)
- Infusion/Injection reactions (weight 2.8%)
- Hypersensitivity reactions (weight 1.1%)
- Flu-like reactions (weight 1.1%)

Risk Difference (per 1000 patients)

Higher for Comparator
Higher for Tysabri
BRAT Tool From a User’s Perspective

**Strengths**

- Convenient to use
  - Easy creation, modification and tuning of the value tree
  - Update of data table structure depending on filter definitions
  - Basic error check capabilities
  - Various options for customization are available

- Provides tabular and graphical overview on benefits and risks
  - Filters allow quick change of ‘perspective’

- Facilitates structured transparent B-R assessment process
BRAT Tool From a User’s Perspective

Limitations

- BRAT tool is designed for the handling of outcomes measured as proportions or rates, but not for categorical or continuous data
- No support of weighting and application of quantitative methods to aid final interpretation and decision making

*Note: These are just limitations of the software tool, not of the framework.*

Recommendation

- The BRAT framework process user’s guide as well as the software user’s guide should always be consulted.
How to properly reduce a **complex multi-dimensional problem** to a “simple” **binary decision**?

- Regulator: to approve the drug (no/yes)
- Insurance: to pay for the drug (no/yes)
- Patient: to take the drug (no/yes)

In the Tysabri case study two quantitative methods were investigated:

1. **Number Needed to Treat (NNT)** – **Number Needed to Harm (NNH)** approach
2. **Multi-Criteria Decision Analysis (MCDA)**
Definition of NNT and NNH

- **Number Needed to Treat** (NNT) is defined as
  \[
  NNT := \frac{1}{p_C - p_T}
  \]
  where \( p_C \) and \( p_T \) denote the proportion of the disease of interest in the control group and the treatment group, respectively.
  
  “The (average) number of patients to be treated in order to avoid one case of the disease”

- Similarly, **Number Needed to Harm** (NNH) is defined as
  \[
  NNH := \frac{1}{q_T - q_C}
  \]
Benefit-Risk Assessment based on NNT/NNH

- Benefit outweighs the risk if

\[
\frac{NNT}{NNH} < 1 \quad (or \text{ alternatively: } NNT < NNH)
\]

- **Limitation:** NNT/NNH approach only works in case of
  - one benefit
  - one risk
  - benefit and risk are of comparable severity
Extension of NNT/NNH concept

- Generalization of NNT/NNH expanding the ideas of Holden (2003) in order to enable
  1. Weighting (here: utility weights)
  2. Multiple risks
  3. Multiple benefits

Simple case:

\[
\frac{NNT}{NNH} = \frac{1}{\frac{(p_C - p_T)}{1} \left( \frac{1}{q_T - q_C} \right)}
\]
Extension of NNT/NNH concept

- Generalization of NNT/NNH expanding the ideas of Holden (2003) in order to enable
  1. Weighting (here: utility weights)
  2. Multiple risks
  3. Multiple benefits

\[
\frac{NNT_w}{NNH_w} := \frac{1}{\sum_{i=1}^{m} (p_{C,i} - p_{T,i}) \cdot (1 - \text{utility}(AE_i^B))} \quad \frac{1}{\sum_{i=1}^{k} (q_{T,i} - q_{C,i}) \cdot (1 - \text{utility}(AE_i^R))}
\]
Extension of NNT/NNH concept

• Benefit-Risk Assessment: Compare weighted NNT with weighted NNH where benefit outweighs risk if

\[
\frac{NNT_w}{NNH_w} < 1
\]

Notes:

• Holden focused on utility weights, however, other types of weights can be used as well

• Weighted NNH (NNH_w) as well as weighted NNT (NNT_w) can no longer be interpreted as a “number of patients to be treated in order ....”.

• Formula from previous slide doesn’t look very handy

Can it be simplified?
Rewriting the formula given in (1) results in

\[
\sum_{i=1}^{m+k} \left( (p_{C,i} - p_{T,i}) \times \text{weight}(AE(i)) \right) > 0
\]

- assuming that the treatment has beneficial events with respect to events \( AE(i) \) (\( i=1,...,m \)), and detrimental effects with respect to events \( AE(i) \) (\( i=m+1,...,k \)).
- \( p_{C,1},..., p_{C,m+k} \) and \( p_{T,1},..., p_{T,m+k} \) denote the proportions of the events \( AE(i) \) (\( i=1,..., m+k \)) in the control and the treatment group, respectively.
- weights are given, for example, by \( (1-\text{utility}()) \).
Extension of NNT/NNH concept -
Weighted Net Clinical Benefit

- Rewriting the formula given in (1) results in

\[
\sum_{i=1}^{m+k} ((p_{C,i} - p_{T,i}) \ast \text{weight}(AE(i))) > 0
\]

- The formula above is the **weighted** version of the ‘Net Clinical Benefit (NCB)’ concept described by Sutton et al. (2005)

- **Tysabri Case Study**: weighted NCB indicates positive benefit-risk balance at initial approval as well as at CHMP reassessment

- **Limitation** of NCB: Benefit and risk criteria need to be measured as proportions (or rates)

  \[=> \textit{Need for methods allowing consideration of categorical and continuous data, too.}\]
A Case Study Using the BRAT Framework for Benefit Risk Assessment

(1) A Generalization of the NNT/NNH concept

Christoph Dierig
Global Integrated Analysis, Bayer Pharma

(2) Application and visualization of Multi-Criteria Decision Analysis (MCDA).

Richard Nixon
Modeling and Simulation, Novartis

Basler Biometric Section, 25 September 2012
Outline

• Explain the process of Multi-criteria Decision Analysis (MCDA)
  – This is a generalization of the weighted Net Clinical Benefit
  – Allows us to compare different outcomes measured on different scales

• Demonstrate some visualizations of Benefit-Risk
  – BR is fundamentally about bringing clarity to a decision maker by clearly communicating the consequences of different drugs
  – Components of BR
  – Deterministic and probabilistic sensitivity analysis
The historical context

• “If I have seen further it is by standing on the shoulders of giants” – Isaac Newton

• Structured Benefit-risk analysis is a relative new idea in drug development, but is build on well established ideas
  – Daniel Bernoulli (1738) – Expected Utility hypothesis
  – Von Neumann and Morgenstern (1944) - Game theory and Economic Behaviour
  – Keeney and Raiffa (1976) - Multi-attribute value theory
MCDA and the Women's heptathlon

<table>
<thead>
<tr>
<th>Event</th>
<th>Jessica Ennis</th>
<th>Value</th>
<th>Lilli Schwarzkopf</th>
<th>Value</th>
<th>Tatyana Chernova</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Javelin throw (m)</td>
<td>47.49</td>
<td>812</td>
<td>51.73</td>
<td>894</td>
<td>46.29</td>
<td>789</td>
</tr>
<tr>
<td>High Jump (cm)</td>
<td>186</td>
<td>1055</td>
<td>183</td>
<td>1016</td>
<td>180</td>
<td>979</td>
</tr>
<tr>
<td>200 metres (s)</td>
<td>22.83</td>
<td>1096</td>
<td>24.77</td>
<td>909</td>
<td>23.67</td>
<td>1013</td>
</tr>
<tr>
<td>Total</td>
<td>2963</td>
<td>2819</td>
<td>2781</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Basler Biometric Section - September 2012 | IMI PROTECT - Tysabri Case Study
MCDA and multiple sclerosis drugs

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Weight</th>
<th>Measure</th>
<th>Value</th>
<th>Benefit-risk</th>
<th>Measure</th>
<th>Value</th>
<th>Benefit-risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relapse</td>
<td>8%</td>
<td>1.46</td>
<td>0.27</td>
<td>0.022</td>
<td>0.47</td>
<td>0.766</td>
<td>0.061</td>
</tr>
<tr>
<td>PML</td>
<td>54%</td>
<td>0</td>
<td>1</td>
<td>0.54</td>
<td>0.0015</td>
<td>0.998</td>
<td>0.54</td>
</tr>
<tr>
<td>Infusion reactions injection reactions</td>
<td>3%</td>
<td>0</td>
<td>1</td>
<td>0.03</td>
<td>0.24</td>
<td>0.764</td>
<td>0.02</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.59</td>
<td></td>
<td></td>
<td>0.62</td>
</tr>
</tbody>
</table>
Step 5: Assess outcome importance

Linear Additive models

- Linear Additive Models with Swing Weights
  - Value functions: Within outcome importance
  - Swing weights: Between outcome importance

Outcome: 2-year relapse rate

Measure = 0.47

Value(measure) = 0.77

Elicited Weight = 8%

BR Contribution = 0.062

Value = 0.77
Step 5: Assess outcome importance

*Three common methods for weight elicitation that use linear additive models*

- Multi-criteria Decision Analysis (MCDA)
- MACBETH (Measuring Attractiveness by a Categorical Based Evaluation Technique)
- AHP (Analytic Hierarchy Process)
Step 5: Assess outcome importance

**MCDA**

For each outcome category

1. Rank outcomes

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Rank</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infusion/injection reactions</td>
<td>1</td>
</tr>
<tr>
<td>Hypersensitivity reactions</td>
<td>2</td>
</tr>
<tr>
<td>Flu-like reactions</td>
<td>3</td>
</tr>
</tbody>
</table>

2. Relative importance

How much more important is it to avoid the top-ranked event compared to the others?

- Infusion/injection reactions
- Hypersensitivity reactions
- Flu-like reactions
Repeat this process all the way up the value tree

The top ranked outcome in each category is carried up the tree

- Move bottom-up through the tree and compare the top-ranked outcomes from each category
- Finally, the top-ranked benefit is compared to the top-ranked risk
- The individual weights for each outcome can then be calculated
Compute the overall weights

Benefits
- Relapse
- Disability Progression
- Convenience

Risks
- Infection
  - Reactivation of serious herpes viral infections
  - PML
- Reproductive Toxicity
  - Congenital abnormalities
- Liver Toxicity
  - Transaminases elevation
- Neurological
  - Seizures
  - Infusion/injection reactions
- Other
  - Hypersensitivity reactions
  - Flu-like reactions

Note that as the weight for a relapse is for a value function with the measure scale with a range from 0 to 2, then actual weight of a single relapse is half that shown here.

PML is 10x worse than disease progression
Example question to assess between outcome importance

- Imagine a clinical trial of 1000 patients with 1 patient developing PML in the treatment arm.
- How many patients would need to have an EDSS progression prevented for you to be indifferent about the benefit and harm caused by the treatment?
MACBETH (Measuring Attractiveness by a Categorical Based Evaluation Technique)

*Qualitative assessment*

- MACBETH is similar to MCDA, except that it provides a different way to get the weights
- **Step 1:** Qualitatively assess how much more attractive it is to move from worst to best for outcome i vs. moving from worst to best for outcome j and keeping everything else at the worst measure (Do this for each pair of criteria)
- **Step 2:** Check consistency of answers
- **Step 3:** Compute initial guess at weights with optimization
- **Step 4:** Refine weights while maintaining consistency
MACBETH

Qualitative assessment

<table>
<thead>
<tr>
<th>PML</th>
<th>Abortion or congenit</th>
<th>Seizures</th>
<th>Reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>PML</td>
<td>no</td>
<td>extreme</td>
<td>extreme</td>
</tr>
<tr>
<td>Abortion or congenit</td>
<td>no</td>
<td>strong</td>
<td>v. strong</td>
</tr>
<tr>
<td>Seizures</td>
<td>no</td>
<td>no</td>
<td>47.83</td>
</tr>
<tr>
<td>Reactivation of ser</td>
<td>no</td>
<td></td>
<td>34.78</td>
</tr>
<tr>
<td>[all zero]</td>
<td></td>
<td></td>
<td>0.00</td>
</tr>
</tbody>
</table>

Consistent judgements

Current scale:
- extreme
- v. strong
- strong
- moderate
- weak
- very weak
- no
AHP (Analytic Hierarchy Process)

*Qualitative assessment*

- Weights are elicited by making pairwise comparisons between criteria
- “How much more important is outcome i vs. outcome j?”
- Must provide number from 1 to 9 on relative scale
- Weight is calculated by finding the dominant eigenvector of the corresponding matrix
- Value functions are computed in a similar manner (do not necessarily come from linear function)
- No consistency check, but rather a score (<0.2 is okay)
Drill down to the values and the weights

**Incremental Benefit-Risk of Tysabri – Placebo**

- This shows which outcomes are contributing most to the total benefit-risk.

- Even though the weight given to PML is large, the incidence is small, leading to a small contribution to the BR.
BRAT Step 6: Display and interpret key metrics

*Incremental Benefit-Risk of Tysabri – Placebo: Waterfall plot*

- The length of each bar gives the contribution to the overall BR.
- End of the last bar gives the overall benefit-risk.
  - Denominated in the BR of one EDSS progression.
- Green = positive BR
- Red = negative BR
- The contribution to the overall BR of PML is very small.
Sensitivity analysis on the weights

Incremental Benefit-Risk of Tysabri – Placebo

- The weights are shown under each bar.
  - The base case weight is shown in the middle, with a +/- 30% range given at the ends.
- The weights are changed one at a time.
- The most important weight is the one given to relapses.
Two way sensitivity analysis on PML

*Incremental Benefit-Risk of Tysabri – Placebo*

- Vary the Tysabri PML incidence (x-axis) and PML weight (each line).
- Increase the weight of PML so that it is 6x larger (to the inferred regulator weight).
- Increase the incidence of PML so that it is twice that observed.
- See that the BR is robust to these changes.
Two way sensitivity analysis on weights

*Incremental Benefit-Risk of Tysabri – Placebo*

- Vary the PML weight (x-axis) and the relapse weight (each line).
- Green line in the middle is the elicited weight. Change by +/- 30%.
- Again the BR is robust to these changes.
### Required Tysabri effect on outcomes to reach a neutral Benefit-Risk vs. Placebo

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Weight</th>
<th>Current Tysabri Effect</th>
<th>Required Tysabri effect</th>
<th>Required Change (Absolute)</th>
<th>New BR</th>
</tr>
</thead>
<tbody>
<tr>
<td>PML</td>
<td>54%</td>
<td>0.15%</td>
<td>6.36%</td>
<td>6%</td>
<td>0.00</td>
</tr>
<tr>
<td>Transaminases elevation</td>
<td>11%</td>
<td>5%</td>
<td>36%</td>
<td>31%</td>
<td>0.00</td>
</tr>
<tr>
<td>Relapse</td>
<td>8%</td>
<td>0.47</td>
<td>1.31</td>
<td>0.84</td>
<td>0.00</td>
</tr>
<tr>
<td>Reactivation of serious herpes viral infections</td>
<td>6%</td>
<td>0%</td>
<td>56%</td>
<td>56%</td>
<td>0.00</td>
</tr>
<tr>
<td>Seizures</td>
<td>5%</td>
<td>1%</td>
<td>68%</td>
<td>67%</td>
<td>0.00</td>
</tr>
<tr>
<td>Congenital abnormalities</td>
<td>5%</td>
<td>0%</td>
<td>67%</td>
<td>67%</td>
<td>0.00</td>
</tr>
<tr>
<td>Disability progression</td>
<td>5%</td>
<td>11%</td>
<td>78%</td>
<td>67%</td>
<td>0.00</td>
</tr>
<tr>
<td>Infusion reactions/injection reactions</td>
<td>3%</td>
<td>24%</td>
<td>100%</td>
<td>76%</td>
<td>0.21</td>
</tr>
<tr>
<td>Flu-like reactions</td>
<td>1%</td>
<td>40%</td>
<td>100%</td>
<td>60%</td>
<td>0.55</td>
</tr>
<tr>
<td>Hypersensitivity Reactions</td>
<td>1%</td>
<td>0%</td>
<td>100%</td>
<td>100%</td>
<td>0.47</td>
</tr>
<tr>
<td>Convenience</td>
<td>1% iv qm hosp</td>
<td>sc od</td>
<td>NA</td>
<td>0.53</td>
<td></td>
</tr>
</tbody>
</table>
Probabilistic sensitivity analysis of the measures

*Incremental Benefit-Risk of Tysabri – Placebo*

- 80% CI are included in the waterfall plot.
- The uncertainty in the overall BR is robust to uncertainty in the outcome measures.
- The components of the uncertainty can be seen.
Take home message

• The BRAT is a framework well suited to benefit-risk analysis

• Benefit-risk analysis is conceptually easy but hard to operationalize – in particular:
  – To define consistent criteria across decision options, find data matching these criteria, and elicit value judgments
  – Squash the messy complexity of real life into a simple model

• A BR assessment does not necessarily give you the answer
  – It is a framework for decomposing and understanding a problem
  – Assesses the main value drivers of a decision
  – Communicates issues in a transparent, rational and consistent way
  – Allows sensitivity analysis around different perspectives (industry, regulator, patient, payer, prescriber)
Acknowledgements

- Thai Son Tong Nguyen – ScHARR, Sheffield
- Isabelle Stoeckert - Bayer
- Silvia Kuhls - Bayer
- Gemma Hodgson - Takeda
- John Pears - Astra Zeneca
- Ioanna Tzoulaki - Imperial
- Dolores Montero - Agencia Española de Medicamentos y Productos Sanitarios
Work Package 5 of PROTECT (membership)

<table>
<thead>
<tr>
<th>Public</th>
<th>Private</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMA</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>DKMA</td>
<td>Bayer</td>
</tr>
<tr>
<td>AEMPS</td>
<td>GSK</td>
</tr>
<tr>
<td>MHRA</td>
<td>Lundbeck</td>
</tr>
<tr>
<td>Imperial College (co-leader)</td>
<td>Merck KGaA (co-leader)</td>
</tr>
<tr>
<td>Mario Negri Institute</td>
<td>Novartis</td>
</tr>
<tr>
<td>CPRD</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>IAPO</td>
<td>Pfizer</td>
</tr>
<tr>
<td></td>
<td>Roche</td>
</tr>
<tr>
<td></td>
<td>Sanofi-Aventis</td>
</tr>
<tr>
<td></td>
<td>Takeda</td>
</tr>
<tr>
<td></td>
<td>Eli Lilly</td>
</tr>
<tr>
<td></td>
<td>Amgen</td>
</tr>
</tbody>
</table>
References

Are there any Questions?